Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Sarayut Lucien Geater · SciRah

Researcher profile · Semantic Scholar

Sarayut Lucien Geater

Prince of Songkla University

Share profile

Sarayut Lucien Geater — researcher profile on SciRah

ORCID iD 0000-0002-3494-8268

h-index: 28
Works: 104
Citations: 13K

Most-cited papers

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
L. Sequist, J. Yang, N. Yamamoto, K. O'Byrne +16 more
2013Journal of Clinical Oncology3,163 citations
Semantic Scholar
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Yi-Long Wu, Cai-Cun Zhou, Cheng-Ping Hu, Ji-Feng Feng +11 more
2014The Lancet Oncology1,931 citations
Semantic Scholar
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
J. Yang, Yi-Long Wu, M. Schuler, M. Sebastian +24 more
2015The Lancet Oncology1,466 citations Open access
Semantic Scholar
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
R. Herbst, G. Giaccone, F. de Marinis, N. Reinmuth +18 more
2020New England Journal of Medicine1,330 citations Open access
Semantic Scholar
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
J. Soria, D. Tan, R. Chiari, Yi-Long Wu +18 more
2017The Lancet1,028 citations
Semantic Scholar
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
J. Yang, L. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai +9 more
2015The Lancet Oncology947 citations Open access
Semantic Scholar
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
N. Rizvi, B. Cho, N. Reinmuth, K. Lee +26 more
2020JAMA Oncology553 citations Open access
Semantic Scholar
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
M. Johnson, B. Cho, A. Luft, J. Alatorre-alexander +15 more
2022Journal of Clinical Oncology381 citations Open access
Semantic Scholar
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
James Chih-Hsin Yang, M. Schuler, N. Yamamoto, K. O'Byrne +16 more
2012Journal of Clinical Oncology205 citations
Semantic Scholar
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
James Chih-Hsin Yang, L. Sequist, Cai-Cun Zhou, M. Schuler +17 more
2016Annals of Oncology191 citations Open access
Semantic Scholar
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
D. Planchard, N. Reinmuth, S. Orlov, J. Fischer +14 more
2020Annals of Oncology144 citations Open access
Semantic Scholar
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
D. Spigel, F. Marinis, G. Giaccone, N. Reinmuth +16 more
2019Annals of Oncology140 citations Open access
Semantic Scholar
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung
Yi-Long Wu, Cai-Cun Zhou, Cheng-Ping Hu, Ji-Feng Feng +11 more
2013European Respiratory Journal99 citations
Semantic Scholar
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
B. Cho, R. Obermannova, A. Bearz, M. McKeage +19 more
2019Journal of Thoracic Oncology65 citations Open access
Semantic Scholar
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
S. Cicėnas, Sarayut Lucien Geater, P. Petrov, Y. Hotko +4 more
2016Lung Cancer65 citations Open access
Semantic Scholar
Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials
Yi-Long Wu, L. Sequist, E. Tan, Sarayut Lucien Geater +17 more
2018Clinical Lung Cancer63 citations Open access
Semantic Scholar
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
Sarayut Lucien Geater, Chong-Rui Xu, Cai-Cun Zhou, Cheng-Ping Hu +11 more
2015Journal of Thoracic Oncology56 citations Open access
Semantic Scholar
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
T. Mok, Sarayut Lucien Geater, W. Su, E. Tan +8 more
2016Journal of Thoracic Oncology54 citations Open access
Semantic Scholar
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
M. Johnson, B. Cho, A. Luft, J. Alatorre-alexander +17 more
2021Journal of Thoracic Oncology49 citations Open access
Semantic Scholar
Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer.
Pritsana Raungrut, Anusara Wongkotsila, K. Lirdprapamongkol, Jisnuson Svasti +4 more
2014Asian Pacific Journal of Cancer Prevention47 citations Open access
Semantic Scholar
A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA)
T. Mok, Keunchil Park, Sarayut Lucien Geater, S. Agarwal +6 more
201235 citations Open access
Semantic Scholar
Cerebral venous thrombosis: comparing characteristics of infective and non-infective aetiologies: a 12-year retrospective study
Pat Korathanakhun, W. Petpichetchian, P. Sathirapanya, Sarayut Lucien Geater
2015Postgraduate medical journal34 citations
Semantic Scholar
Predictors of hospital outcome in patients with cerebral venous thrombosis.
Pat Korathanakhun, P. Sathirapanya, Sarayut Lucien Geater, W. Petpichetchian
2014Journal of Stroke & Cerebrovascular Diseases34 citations
Semantic Scholar
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
S. Peters, B. Cho, A. Luft, J. Alatorre-alexander +16 more
2022Journal of Thoracic Oncology32 citations Open access
Semantic Scholar
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
L. Sequist, Jie Yang, N. Yamamoto, K. O'Byrne +16 more
2023Journal of Clinical Oncology31 citations
Semantic Scholar
Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.
T. Dechaphunkul, T. Arundon, Ponpis Raungkhajon, R. Jiratrachu +2 more
2021Clinical Nutrition31 citations
Semantic Scholar
ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Keunchil Park, Chun-Ming Tsai, M. Ahn, Chong-Jen Yu +16 more
201227 citations
Semantic Scholar
Bronchial Artery Embolization in Life-Threatening Hemoptysis: Outcome and Predictive Factors
K. Dorji, Keerati Hongsakul, Warissara Jutidamrongphan, Maliwan Oofuvong +1 more
2021Journal of the Belgian Society of Radiology26 citations Open access
Semantic Scholar
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
E. Garon, B. Cho, N. Reinmuth, K. Lee +16 more
2021Clinical Lung Cancer25 citations Open access
Semantic Scholar
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment.
D. Kowalski, N. Reinmuth, S. Orlov, J. Fischer +13 more
2018Annals of Oncology24 citations Open access
Semantic Scholar
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
Yi-Long Wu, V. Hirsh, L. Sequist, Cheng-Ping Hu +13 more
2017Patient24 citations Open access
Semantic Scholar
Single nucleotide polymorphisms in the Gc gene for vitamin D binding protein in common cancers in Thailand.
Wanwisa Maneechay, T. Boonpipattanapong, Samornmas Kanngurn, P. Puttawibul +2 more
2015Asian Pacific Journal of Cancer Prevention24 citations Open access
Semantic Scholar
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
D. Trukhin, E. Poddubskaya, Z. Andrić, Tamta Makharadze +94 more
2021BioDrugs23 citations Open access
Semantic Scholar
Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer
Keson Trakunram, Pichitpon Chaniad, Sarayut Lucien Geater, W. Keeratichananont +5 more
2020Cancer Biology and Medicine21 citations Open access
Semantic Scholar
Differences in cancer incidence among predominantly Muslim and Buddhist subpopulations in Songkhla.
H. Sriplung, Surichai Bilheem, Tirada Kuntipundee, Sarayut Lucien Geater
2014Asian Pacific Journal of Cancer Prevention19 citations Open access
Semantic Scholar
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
M. Ahn, M. Mendoza, N. Pavlakis, T. Kato +17 more
2022Clinical Lung Cancer16 citations Open access
Semantic Scholar
The hidden financial catastrophe of chronic kidney disease under universal coverage and Thai “Peritoneal Dialysis First Policy”
Pornpen Sangthawan, P. Klyprayong, Sarayut Lucien Geater, P. Tanvejsilp +14 more
2022Frontiers in Public Health16 citations Open access
Semantic Scholar
OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
B. Cho, R. Obermannova, A. Bearz, Dohoung Kim +12 more
201716 citations Open access
Semantic Scholar
LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.
Sarayut Lucien Geater, Cai-Cun Zhou, Cheng-Ping Hu, Ji-Feng Feng +11 more
201315 citations
Semantic Scholar
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
T. Reungwetwattana, B. Cho, K. Lee, Y. Pang +18 more
2023Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.
C.-C. Lin, M. Taylor, V. Boni, P. Brunsvig +16 more
2018Annals of Oncology14 citations Open access
Semantic Scholar
PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
G. Castro, D. Tan, L. Crinò, Yi-Long Wu +15 more
201713 citations Open access
Semantic Scholar
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
T. Mok, Sarayut Lucien Geater, N. Iannotti, S. Thongprasert +10 more
2014Annals of Oncology13 citations Open access
Semantic Scholar
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.
N. Reinmuth, B. Cho, K. Lee, A. Luft +14 more
2019Annals of Oncology12 citations Open access
Semantic Scholar
Prevalence, associated factors, and clinical consequences of metabolic syndrome in chronic obstructive pulmonary disease patients: a 5-year prospective observational study
W. Keeratichananont, P. Kaenmuang, Sarayut Lucien Geater, P. Manoret +1 more
2023Therapeutic Advances in Respiratory Disease11 citations Open access
Semantic Scholar
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
D. Tan, Sarayut Lucien Geater, Chong-Jen Yu, Chun-Ming Tsai +10 more
2020JTO Clinical and Research Reports11 citations Open access
Semantic Scholar
Methylation of 14-3-3σ gene and prognostic significance of 14-3-3σ expression in non-small cell lung cancer
Pritsana Raungrut, Pingpond Petjaroen, Sarayut Lucien Geater, W. Keeratichananont +3 more
2017Oncology Letters10 citations Open access
Semantic Scholar
LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
F. Griesinger, M. Johnson, B. Cho, A. Luft +18 more
2022Annals of Oncology9 citations Open access
Semantic Scholar
Utility of prophylactic percutaneous endoscopic gastrostomy tube in head and neck cancer patients undergoing concurrent chemoradiation: A prospective observational cohort.
T. Dechaphunkul, Pawitra Soonthornrak, Sarayut Lucien Geater, A. Dechaphunkul
2022American Journal of Otolaryngology9 citations Open access
Semantic Scholar
Diagnostic and prognostic value of serum miR-145 and vascular endothelial growth factor in non-small cell lung cancer
Sarayut Lucien Geater, Pichitpon Chaniad, Keson Trakunram, W. Keeratichananont +3 more
2021Oncology Letters9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Mok×12
Invite
T. Mok — researcher profile on SciRah
Yi-Long Wu×12
Invite
Yi-Long Wu — researcher profile on SciRah
Chun-Ming Tsai×10
Invite
Chun-Ming Tsai — researcher profile on SciRah
D. Massey×10
Invite
D. Massey — researcher profile on SciRah

×9

Invite

S. Orlov — researcher profile on SciRah

Invite

L. Sequist — researcher profile on SciRah

Invite

N. Yamamoto — researcher profile on SciRah

Invite

K. Lee — researcher profile on SciRah

Invite

M. Schuler — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Invite

K. O'Byrne — researcher profile on SciRah

Invite

V. Hirsh — researcher profile on SciRah